Concurrent Investment Advisors LLC Purchases 15,189 Shares of AstraZeneca PLC (NASDAQ:AZN)

Concurrent Investment Advisors LLC boosted its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 89.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 32,114 shares of the company's stock after buying an additional 15,189 shares during the period. Concurrent Investment Advisors LLC's holdings in AstraZeneca were worth $2,360,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Banque Transatlantique SA acquired a new position in shares of AstraZeneca during the fourth quarter valued at about $26,000. Confluence Investment Management LLC acquired a new position in shares of AstraZeneca during the first quarter valued at about $27,000. Mascagni Wealth Management Inc. acquired a new stake in shares of AstraZeneca in the 4th quarter worth about $29,000. FNY Investment Advisers LLC acquired a new stake in shares of AstraZeneca in the 1st quarter worth about $29,000. Finally, Highline Wealth Partners LLC raised its holdings in shares of AstraZeneca by 447.4% in the 1st quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock worth $31,000 after acquiring an additional 340 shares during the last quarter. Institutional investors and hedge funds own 20.35% of the company's stock.

AstraZeneca Price Performance

Shares of AZN traded up $0.84 during midday trading on Tuesday, reaching $70.47. The stock had a trading volume of 997,810 shares, compared to its average volume of 5,245,151. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $87.68. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.65. The company's 50-day moving average is $70.77 and its 200 day moving average is $70.71. The company has a market capitalization of $218.55 billion, a price-to-earnings ratio of 28.26, a price-to-earnings-growth ratio of 1.28 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 EPS for the quarter, beating analysts' consensus estimates of $1.10 by $0.14. The company had revenue of $13.59 billion during the quarter, compared to the consensus estimate of $13.71 billion. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.06 earnings per share. On average, equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, BNP Paribas started coverage on shares of AstraZeneca in a report on Tuesday, April 15th. They issued an "outperform" rating and a $75.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat.com, AstraZeneca currently has an average rating of "Moderate Buy" and a consensus price target of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.